Macmillan Cancer Support: If patients are to be offered the right care, all information about drug trials should be published and available for scrutiny, not just the data which presents a new treatment in the most favourable light. This is currently not happening, and people have been unnecessarily harmed because of it. It is particularly important for cancer patients, as a large proportion of new drugs in the pipeline are cancer drugs.